Search
Atovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Mixtures: Malarone 250 mg/100 mg Filmtabletten, Atovaquon/Proguanilhydrochlorid STADA 250 mg/100 mg FilmtablettenProducts: ATOVAQUONE E PROGUANILE SANDOZVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalin combination with sofosbuvir for all six genotypes of Hepatitis C [L852]. … It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and
Mixtures: VOSEVİ 400 MG/ 100 MG/ 100 MG FİLM KAPLI TABLET, 28 ADETTanespimycin
go.drugbank.com/drugs/DB05134InvestigationalTanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).
Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15680ApprovedInvestigationalNeisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15681ApprovedInvestigationalProducts: NeisVac-C Injektionssuspension in einer FertigspritzeVusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigationalon anti-PD-1 therapy. … [L64061] The virus is engineered to express a fusogenic glycoprotein derived from gibbon ape leukemia virus (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), and has its
Talactoferrin alfa
go.drugbank.com/drugs/DB05426InvestigationalTalactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix.
CCX915
go.drugbank.com/drugs/DB05159ExperimentalThe CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]
GI-101
go.drugbank.com/drugs/DB17243InvestigationalGI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety